UroGen Pharma Ltd. — Director's Dealing 2020

Feb 4, 2020

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: UroGen Pharma Ltd. (URGN)
CIK: 0001668243
Period of Report: 2020-01-31

Reporting Person: Schoenberg Mark (Chief Medical Officer)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2020-01-31	Stock options (right to buy)	$29.41	A	15000	Acquired		Ordinary Shares (15000)	Direct
2020-01-31	Restricted stock unit	$	A	6000	Acquired		Ordinary Shares (6000)	Direct

Footnotes

F1: 1/3rd of the shares underlying the stock option vest on January 31, 2021 and 1/12th of the shares underlying the stock option vest in 8 quarterly installments thereafter, subject to the Reporting Person's continuous service with the Issuer on each respective vesting date.

F2: Each restricted stock unit ("RSU") represents a contingent right to receive one ordinary share of the Issuer.

F3: 1/3rd of the shares underlying the RSU vest on January 31, 2021 and 1/12th of the shares underlying the RSU vest in 8 quarterly installments thereafter, subject to the Reporting Person's continuous service with the Issuer on each respective vesting date.